Barclays Lowers Evolent Health (NYSE:EVH) Price Target to $19.00

Evolent Health (NYSE:EVH) had its price objective reduced by Barclays from $39.00 to $19.00 in a research note published on Monday,Benzinga reports. Barclays currently has an overweight rating on the technology company’s stock.

A number of other research analysts have also recently issued reports on EVH. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $38.00 to $16.00 in a research report on Friday, November 8th. JMP Securities decreased their price target on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Citigroup dropped their price objective on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. KeyCorp began coverage on shares of Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 price target on shares of Evolent Health in a report on Tuesday, October 8th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $29.50.

Evolent Health Trading Down 0.6 %

Shares of EVH stock opened at $12.67 on Monday. Evolent Health has a fifty-two week low of $12.31 and a fifty-two week high of $35.00. The stock’s fifty day moving average price is $25.47 and its two-hundred day moving average price is $24.45. The company has a quick ratio of 1.08, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Insider Activity

In related news, COO Emily Ann Rafferty sold 8,861 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $265,830.00. Following the transaction, the chief operating officer now owns 63,408 shares in the company, valued at $1,902,240. The trade was a 12.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Daniel Joseph Mccarthy sold 23,693 shares of the stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the sale, the president now owns 198,809 shares of the company’s stock, valued at approximately $6,141,210.01. The trade was a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 307,291 shares of company stock valued at $9,290,385. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Evolent Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Evolent Health by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 10,915,070 shares of the technology company’s stock worth $357,905,000 after purchasing an additional 93,739 shares in the last quarter. RA Capital Management L.P. lifted its holdings in shares of Evolent Health by 125.0% in the 1st quarter. RA Capital Management L.P. now owns 5,736,132 shares of the technology company’s stock worth $188,088,000 after purchasing an additional 3,187,000 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Evolent Health by 35.2% in the 2nd quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after purchasing an additional 1,308,376 shares in the last quarter. Engaged Capital LLC grew its position in Evolent Health by 26.1% in the 2nd quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock valued at $78,611,000 after purchasing an additional 850,000 shares during the period. Finally, Eventide Asset Management LLC increased its stake in Evolent Health by 1.7% during the 3rd quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock valued at $107,580,000 after purchasing an additional 64,985 shares in the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.